SUNPHARMA.NS - Sun Pharmaceutical Industries Limited

NSE - NSE Real Time Price. Currency in INR
-11.45 (-2.09%)
At close: 7:29PM IST
Stock chart is not supported by your current browser
Previous Close547.20
Bid0.00 x 0
Ask535.75 x 0
Day's Range532.00 - 543.00
52 Week Range432.70 - 759.00
Avg. Volume4,983,737
Market Cap1.29T
PE Ratio (TTM)28.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters10 days ago

    BRIEF-Sun Pharmaceutical Industries says unit raises shareholding in Ranbaxy Malaysia Sdn Bhd

    Oct 12 (Reuters) - Sun Pharmaceutical Industries Ltd * Unit agreed to increase shareholding in Ranbaxy Malaysia Sdn Bhd via purchase of 666,985 shares of Ranbaxy Malaysia Source text - ...

  • Reuters10 days ago

    Sensex rises ahead of key corporate results

    REUTERS - Indian shares extended gains on Thursday with the NSE index clocking its biggest percentage gain since May 25 as excitement builds up ahead of some key quarterly results including that from Tata ...

  • Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge
    Bloomberg26 days ago

    Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge

    While India’s largest pharmaceutical companies have seen drug approvals in the U.S. slow overall, their research and development spending has been on a run. Not so for Aurobindo Pharma Ltd.Quarter after ...

  • Reuters2 months ago

    Morning News Call - India, August 14

    To access the newsletter, click on the link: If you would like to receive this newsletter via email, please register ...

  • Billionaire Shanghvi's Sun Pharma Surprises With Loss
    Bloomberg2 months ago

    Billionaire Shanghvi's Sun Pharma Surprises With Loss

    The billionaire founder of Sun Pharmaceutical Industries Ltd. pledged that the drugmaker would do better after reporting its first loss in at least 12 years amid regulatory headaches and a weakening market ...

  • Reuters3 months ago

    No more freebies? India plans crackdown on marketing by drugmakers

    India, one of the world's largest markets for pharmaceuticals is drawing up its first set of marketing rules for drugmakers, restricting gifts and trips offered to doctors and pharmacists to 1,000 rupees ($15), according to a draft proposal seen by Reuters. Such rules are common overseas, but are not set in stone in India, where campaigners have long demanded a crackdown on unethical selling practices that include gifts ranging from electrical appliances to foreign trips to woo physicians and pharmacists into prescribing and stocking specific medicines. The country has voluntary marketing guidelines for drugmakers, but critics say they are ineffective.

  • Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
    Bloomberg5 months ago

    Sun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year

    Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, warned investors that sales could decline in the coming year amid downward pressure on generic-drug prices in the U.S. and regulatory issues ...

  • Reuters5 months ago

    India's drugmakers need more time to meet intl standards-industry group

    India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries.

  • Bloomberg6 months ago

    U.S. FDA Finds Incomplete Lab Records at Sun Pharma Plant

    The U.S. Food and Drug Administration noted incomplete laboratory records among potential manufacturing violations it observed during an inspection of Sun Pharmaceutical Industries Ltd.’s Dadra unit this ...

  • Reuters7 months ago

    Indian drugmakers face squeeze in U.S. healthcare market

    India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.

  • Indian Pharma Exits the Trauma Room
    Bloomberg7 months ago

    Indian Pharma Exits the Trauma Room

    Now they just have to survive Dr. Trump's trade prescriptions.

  • Reuters8 months ago

    Sun Pharma's profits drop as U.S. sales hit by pricing, supply issues

    Sun Pharmaceutical Industries , India's largest drugmaker, reported its first fall in quarterly profits in a year on Tuesday, as pricing issues and supply constraints affected sales in the United States, its largest market. Sun's U.S. business faces increasing uncertainty as it struggles to fix quality control problems found by regulators at its key drug factories, and is the subject of a U.S. Department of Justice investigation into increases in drug prices.

  • Reuters8 months ago

    India's Sun Pharma Q3 profit falls nearly 5 pct; below estimates

    India's largest drugmaker Sun Pharmaceutical Industries Ltd's third-quarter profit fell below analysts' estimates due to slower sales in the United States, its largest market. Sun's net profit for the ...

  • Bloomberg10 months ago

    U.S. FDA Found Testing, Reporting Shortfalls at Sun Pharma Plant

    U.S. Food and Drug Administration inspectors in a recent visit to Sun Pharmaceutical Industries Ltd.’s plant in Halol, India, found that some testing programs weren’t adequately designed, and that failing ...

  • Bloomberg10 months ago

    Sun Pharma Halol Plant Review Resulted in 14-Page FDA Report

    A U.S. Food & Drug Administration inspection of Sun Pharmaceutical Industries Ltd.’s facility in Halol, India, has given rise to a 14-page inspection report that could list potential violations of the ...

  • TheStreet.com11 months ago

    Sun's Taro Unit Names New CEO Amid Generics Investigation

    The India pharma giant also purchases an 85.1% interest in Biosintez for $60 million.